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An integrated drug repurposing 
strategy for the rapid identification 
of potential SARS‑CoV‑2 viral 
inhibitors
Alfonso trezza1,3, Daniele Iovinelli1,3, Annalisa Santucci1, Filippo Prischi2* & Ottavia Spiga1*
The Coronavirus disease 2019 (COVID‑19) is an infectious disease caused by the severe acute 
respiratory syndrome‑coronavirus 2 (SARS‑CoV‑2). The virus has rapidly spread in humans, causing 
the ongoing Coronavirus pandemic. Recent studies have shown that, similarly to SARS‑CoV, SARS‑
CoV‑2 utilises the Spike glycoprotein on the envelope to recognise and bind the human receptor ACE2. 
This event initiates the fusion of viral and host cell membranes and then the viral entry into the host 
cell. Despite several ongoing clinical studies, there are currently no approved vaccines or drugs that 
specifically target SARS‑CoV‑2. Until an effective vaccine is available, repurposing FDA approved 
drugs could significantly shorten the time and reduce the cost compared to de novo drug discovery. In 
this study we attempted to overcome the limitation of in silico virtual screening by applying a robust 
in silico drug repurposing strategy. We combined and integrated docking simulations, with molecular 
dynamics (MD), Supervised MD (SuMD) and Steered MD (SMD) simulations to identify a Spike protein 
– ACE2 interaction inhibitor. Our data showed that Simeprevir and Lumacaftor bind the receptor‑
binding domain of the Spike protein with high affinity and prevent ACE2 interaction.
The World Health Organisation (WHO) declared the Coronavirus disease (COVID-19) outbreak a pandemic 
on March 12th 2020, and as of May 21st, over 4,893,186 cases and 323,256 deaths have been reported (https ://
www.who.int/emerg encie s/disea ses/novel -coron aviru s-2019/situa tion-repor ts/). The Severe acute respiratory 
syndrome–coronavirus 2 (SARS-CoV-2) was identified as the viral agent causing the disease. SARS-CoV-2 
is closely related to the SARS-CoV, which caused a pandemic in 2002–20031, and it is believed to be the third 
member of the Coronaviridae family to cause severe respiratory diseases in  human2. Despite several ongoing 
clinical studies, there are currently no approved vaccines or drugs that specifically target SARS-CoV-2.
SARS-CoV-2 has a single-stranded positive-sense RNA composed of 29,903 nt containing five genes, ORF1ab 
(codifying 16 non-structural proteins), spike (S), envelope (E), membrane (M) and nucleocapsid (N)  genes3. The 
virus uses the S homotrimeric glycoprotein located on the virion surface to allow entry into the human  cells4. 
The S protein goes through major structural rearrangements to mediate viral and human cell membranes fusion. 
The process is initiated by the binding of the receptor-binding domain (RBD) of the S1 subunit to the peptidase 
domain (PD) of angiotensin-converting enzyme 2 receptor (ACE2) on the host  cell5. Structural studies have 
shown that two S protein trimers can simultaneously bind to one ACE2  dimer6. This induces a conformational 
change that expose a proteolytic site on the S protein, which is cleaved by the cellular serine protease  TMPRSS27. 
Dissociation of S1 induces transition of the S2 subunit to a post fusion conformation, with exposed fusion 
 peptides8, which allows endocytic entry of  virus9. Wrapp et al.10 have shown that, despite SARS-CoV-2 and SARS-
CoV sharing a similar cell entry mechanism, SARS-CoV-2 S protein binds ACE2 with a 10- to 20-fold higher 
affinity than SARS-CoV S, which may be related to the higher person-to-person transmission of SARS-CoV-2.
S glycoprotein is highly immunogenic, and it is a promising target for drug  design11. We showed that a 
combination of four 20-mer synthetic peptides disrupting SARS-CoV S heterotrimer reduced or completely 
inhibited infectivity in vitro12. Similarly, antibodies targeting SARS-CoV S protein neutralize the virus and 
open
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have potential for  therapy13. In fact, disruption of the binding of the S protein to ACE2 prevents the virus from 
attaching to the host  cell14.
The social and economic impact of COVID-19 and the possibility of future similar pandemics are pushing 
for the rapid development of treatments. As such, targeting viral-host protein–protein interaction (PPI) may 
represent a promising way to prevent or reduce the spreading of the virus before a vaccine is  available15. In this 
study we performed an extensive analysis of the intrinsic dynamic, structural properties and drug targeting 
of SARS-CoV-2 RDB. In particular starting from the structure of RDB in complex with ACE2, we identified 
transient pockets on RDB on the ACE2 interaction surface area. Our data provide detailed information on the 
dynamic features of RDB that we exploited for docking studies. We carried out a virtual screening using 1582 
FDA-approved drugs to explore new therapeutic benefits of existing drugs. To take into account unique features 
of molecules, such as conformational flexibility, charges distribution, and solvent role in target recognition and 
binding, we performed an extensive molecular dynamics simulation analysis. By combining molecular dynamics 
simulations (MD), Supervised MD (SuMD), Steered MD (SMD) and interaction energy calculations, we showed 
that Simeprevir and Lumacaftor bind RDB with high affinity and prevent ACE2 interaction. Overall, by adopt-
ing a robust in silico approach, our results could open the gates toward the development of novel COVID-19 
treatments.
Methods
Structural resources. 3D Structure and FASTA sequence of SARS-CoV-2 RBD in complex with human 
hACE2 (PDB ID 6LZG) were retrieved from the RCSB Protein Data  Bank16. To avoid errors during the molecu-
lar dynamic (MD) simulations, missing side chains and steric clashes in PDB files were adjusted through homol-
ogy modelling, using PyMOD2.0 and MODELLER v.9.317. 3D structures were validated using  PROCHECK18. 
GROMACS 2019.319 with charmm36-mar2019 force field was used to resolve high energy intramolecular inter-
action before docking simulations, and CGenFF was used to assign all parameters to ligands. Structures were 
immersed in a cubic box filled with TIP3P water molecules and counter ions to balance the net charge of the 
system. Simulations were run applying periodic boundary conditions. The energy of the system was minimized 
with 5.000 steps of minimization with the steepest descent algorithm and found to converge to a minimum 
energy with forces less than 100 kJ/mol/nm. A short 10 ns classic Molecular Dynamics (cMD) was performed 
to relax the system.
All the cMD simulations were performed integrating each time step of 2 fs; a V-rescale thermostat maintained 
the temperature at 310 K and Berendsen barostat maintained the system pressure at 1 atm, with a low dumping 
of 1 ps−1; the LINCS algorithm constrained the bond lengths involving hydrogen atoms.
Transient pockets and virtual screening. A 100 ns cMD simulation was used, as described above, for 
the identification of transient pockets. Transient pockets were identified by analysing MD trajectories of SARS-
CoV-2 RBD structure with EPOS  tool20, using parameters by default. The volumes of the transient pockets dur-
ing the simulation were measured using  POVME21. Open pockets in close proximity to ACE2 binding site were 
selected based on the depth and polarity of the cavity. A box with dimensions of 25, 35, and 20 Å was created 
around the transient pocket using Autodock  Tools22. Subsequently, a virtual screening using the FDA-approved 
drug library available on  DrugBank23 was carried out on SARS-CoV-2 RBD using AutoDock/VinaXB24. MGL-
TOOLS  scripts22 and  OpenBabel25 were used to respectively convert protein and ligand files and to add gasteiger 
partial charges. The full FDA-approved library was downloaded from  DrugBank23 and a total of 1,582 molecules, 
corresponding to the number of structures successfully processed by OpenBabel, was used for the virtual screen-
ing. Drugs names and structures used in this study are available on https ://githu b.com/fpris chi/Suppl ement 
ary_FDAli brary .git
Supervised molecular dynamics (SuMD) simulations. SuMD were used to sample the binding of 
hACE2 to RBD and to probe the binding of hACE2 to RBD-Simeprevir/Lumacaftor complexes. SuMD method-
ology relies on a tabu-like algorithm that monitors the distance between hACE2 and centre of mass of the RBD 
binding site during unbiased MD simulations to sample a binding event in the range of  nanoseconds26. The pro-
tocol is based on performing a series of short unbiased MD simulations, where after each simulation the distance 
points collected at regular time intervals are fitted into a linear function. If the resulting slope is negative, then 
hACE2 is getting closer to the RBD binding site and the MD steps are kept. If the slope is not negative, then the 
simulation is restarted by randomly assigning the atomic velocities. We used an SuMD step of 1,000 ps with a 
constant temperature and pressure of 310 K and 1 atm respectively. When the distance between the hACE2 and 
RBD reached 5 Å or less, then the supervision was disabled and a 10 ns cMD simulation was performed. The 
analysis was performed with an in-house written python and bash script.
Steered molecular dynamics (SMD) simulations. In order to evaluate the binding interaction between 
RBD and Simeprevir or Lumacaftor, the RBD-Simeprevir/Lumacaftor complexes were simulated to dissociate 
using a 700 ps SMD simulation by Constant Force Pulling of 250 kJ/mol/nm. While the backbone of RBD was 
not allowed to move, Simeprevir and Lumacaftor experienced a constant force in x, y, z direction, specifically 
(250, 0, 0) for both compounds. Simeprevir and Lumacaftor were pulled with an external force in the NPT 
ensemble at 1 atm and 310 K with 2 fs time steps. MD analyses was performed with GROMACS 2019.3 package 
and displayed with GRACE.
Protein–ligand interaction energy. To quantify the strength of the interaction between the RBD and 
Simeprevir/Lumacaftor, we computed the nonbonded interaction energy. GROMACS has the ability to decom-
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pose the short-range nonbonded energies via the energygrps keyword in the .mdp file. The energy terms of inter-
est are the average short-range Coulombic interaction energy (Coul-SR) and the short-range Lennard–Jones 
energy (LJ-SR). The total interaction energy  (IEBinding) is defined by:
Results
SARS‑CoV‑2 S glycoprotein virtual screening. SARS-CoV-2 RBD and hACE2 binding is mostly 
driven by polar interaction, with an overall ~ 900 Å2 buried surface area. A close analysis of the interface reveals 
the absence of cavities on RBD in the interaction surface. We performed MD simulations to account for the 
protein conformational flexibility and detected 1,029 transient pockets. Based on the druggability features of the 
cavities, i.e. volume, depth, polarity, and proximity to the hACE2 binding site, we detected a cluster of 9 transient 
pockets. In order to identify possible PPI inhibitors the transient pocket that contained key residues involved in 
hACE2 recognition and binding (Fig. 1A) was selected and used for the virtual screening of 1582 FDA-approved 
drugs. This curated library of drugs, whose structures were freely downloaded from  DrugBank23, represents a 
reservoir of bioactive molecules that could be repurposed for COVID-19 treatment relatively fast, due to their 
pre-existing approval for use in humans. The 10 best compounds (Lumacaftor, Paritaprevir, Dihydroergotamine, 
Trypan blue, Midostaurin, Dihydroergotoxine, Simeprevir, Lurasidone, Spinosyn D, Olaparib) showed high 
binding free energy scores (− 9.4 to − 8.5 kcal/mol) (Fig. S1). The compound with the highest binding energy 
(− 9.4 kcal/mol) was Lumacaftor, a CFTR corrector that traffic the mutant protein to the plasma  membrane27. 
An analysis of the quality of interactions of the 10 best compounds revealed that Simeprevir had the highest 
number of polar bonds with side chains of residues in the RBD binding pocket. Simeprevir, a second-generation 
HCV NS3/4A protease  inhibitor28, has been reported to be both a SARS-CoV-2 main protease  inhibitor29 and a 
S protein-RBD interaction  inhibitor30. Simeprevir forms an extended network of H-bonds with Arg403, Lys417, 
Gln493, Gly496 and Tyr505, and forms Van Der Waals interactions with Tyr421, Tyr453 and Tyr505 (Fig. 1B). 
Differently, Lumacaftor has a higher number of hydrophobic contacts, compared to Simeprevir, specifically with 
Tyr453, Leu455, Tyr495, Phe497 and Tyr505, with the potential formation of π-stacking using the Cζ, of Arg403, 
and forms H-bonds with Gln409, Lys417 and Asn501 (Fig. 1C). Analysis of the crystal structure of RBD in 
complex with ACE2 reveals that the residues involved in the binding with the two drugs are key drivers of RBD 
and ACE2  interaction6. Of particular interest are residues Lys417, Leu455 and Gln493, which are not conserved 
IEBinding = Coul− SR + LJ− SR
Figure 1.  RBD binding pocket and drugs bindg site. (A) Surface representation of the structure of the 
RBD of the S protein having an open pocket conformation. The transient pocket surface patch is depicted 
in brown. In the zoomed region it is possible to see a detailed structural representation of the open pocket 
conformation. Residues laying on the pocket surface have been labelled and are shown in stick. (B, C) Structural 
representations of the (B) RBD-Simeprevir and (C) RBD-Lumacaftor complexes resulting from docking 
simulations. Residues forming direct interactions with the drugs are shown as brown sticks. Hydrogen bonds are 
indicated with yellow dashed lines.
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in SARS-CoV and have been linked to the higher affinity of SARS-CoV-2 S protein for  ACE26. Taken together, 
these data show that Simeprevir and Lumacaftor are able to form clearly defined specific interactions with the 
SARS-CoV-2 S glycoprotein and are promising PPI competitive inhibitors.
Simeprevir and lumacaftor inhibit RBD‑ACE2 binding in silico. In order to understand if Sime-
previr and Lumacaftor are able to interfere and prevent the binding between the S glycoprotein and ACE2, we 
ran a Supervised Molecular Dynamics (SuMD) simulations. Using SuMD it is possible to simulate the full bind-
ing process of ACE2 to RBD in presence of Simeprevir or Lumacaftor in an unbiased way (i.e. independently 
from starting relative positions), taking into account hydration patterns and drug binding-unbinding events. We 
first validated the SuMD protocol by simulating the binding process of RBD with ACE2. The resulting relative 
position of ACE2 bound to RBD is comparable to that in the crystal structure (Fig. S2). The interaction between 
ACE2 and RBD is established after 16 ns of productive trajectory and is mediated by key residues in the recep-
tor binding motif (RBM). Specifically, SARS-CoV-2 Tyr453, Asn487, Tyr489, Gln498, Asn501 and Tyr505 form 
H-bonds with ACE2, whereas SARS-CoV-2 Phe486 interacts with ACE2 via van der Waals forces. Outside the 
RBM, we see the formation of the salt bridge between SARS-CoV-2 Lys417 and ACE2 Asp30 in line with pub-
lished data suggesting that this key interaction contributes to the difference in affinity between SARS-CoV and 
SARS-CoV-2 S proteins for  ACE25. Using the same approach we then simulated the binding of ACE2 to RBD 
bound to Simeprevir or Lumacaftor. During the SuMD simulation ACE2 did not displace the drugs and did 
not form interactions with the S glycoprotein even after 50 ns of simulation. This is very likely due to the drugs 
interacting with the side chains of the key residues Lys417, Tyr453, Asn501 and Tyr505, which prevent ACE2 
target recognition. Taken together these data show that Simeprevir and Lumacaftor prevent ACE2 recognition 
and binding to the S glycoprotein.
Simeprevir and lumacaftor binding stability. During the SuMD drugs were allowed to move and find 
a more energetically favourable pose in the binding pocket. We noticed very limited movements of Simeprevir 
and Lumacaftor and, to confirm binding stability, we performed 100 ns cMD simulations of RBD alone and in 
complex with the drugs. The pose of Simeprevir and Lumacaftor did not change significantly during the simula-
tion, and the RMSD average was 2.4 Å and 3.2 Å respectively (Figs. S3 and 2A). In order to exclude presence 
of artefacts in our analysis, we monitored the protein structural integrity during the simulations. We noticed 
limited differences between the RMSD of the apo protein (1.8 Å) and the RMSD of RBD bound to Simeprevir 
or Lumacaftor (1.3 and 1.4 Å respectively), which excludes presence of different protein structural rearrange-
ments in the three cMD simulations (Fig. 2B). To quantify the strength of the interaction between Simeprevir 
and Lumacaftor on RBD, we computed the interaction energy between the protein and the two drugs. The total 
interaction energy for Simeprevir and Lumacaftor was − 75.58 ± 4.2 kJ/mol and − 63.42 ± 13.8 kJ/mol respec-
tively. Taken together these data suggest that Simeprevir and Lumacaftor bind spontaneously to the target with 
high affinity.
Figure 2.  Root mean square deviation (RMSD) plots. (A) The RMSD profile of drugs and protein backbone, 
(B) relative to the initial frame against simulation time.
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Drugs‑protein unbinding simulations. To further characterise the recognition process of the two drugs 
to the S glycoprotein we performed Steered Molecular Dynamics (SMD) simulations. We ran a 800 ps SMD 
simulation on RBD in complex with both Simeprevir and Lumacaftor, and the time-averaged force profiles dur-
ing the unbinding simulation of complexes is shown in Fig. 3A. Both drugs have a steady increase of the applied 
forces on the first ~ 150 and ~ 200 ps of the simulation, respectively for Lumacaftor and Simeprevir, until they 
reach the maximum, which corresponds to the rupture force of Lumacaftor and Simeprevir unbinding along 
this dissociation pathway. The force then quickly decreases and stays constant until the end of the simulation. In 
the first step, between 0 and 315 ps of the simulation for Simeprevir and 0 and 354 ps for Lumacaftor, the two 
drugs slowly detach and move away from the transient pocket; in the second step, between 316 and 800 ps of the 
simulation for Simeprevir and 355 and 800 ps for Lumacaftor, they move away from the protein and enter the 
solvent region (Fig. 3B,C). The comparable rupture forces reflect similarity in the unbinding from RBD in line 
with our binding energy data.
Figure 3.  Steered Molecular Dynamics simulations. (A) Force profiles of drugs pulled out of the RDB transient 
pocket along the unbinding pathway, Lumacaftor (dotted line) and Simeprevir (continuous line). (B, C) 
Structural representations showing position of Lumacaftor (cyan ball-and-stick) and Simeprevir (green ball-
and-stick) on RBD (white cartoon) during the different stages of the unbinding process from the RBD binding 
pocket (brown surface).
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Discussion
SARS-CoV-2 invades human cells via ACE2, a transmembrane protein expressed on the surface of alveolar 
cells of the lungs. Upon binding of ACE2, viral and host cell membranes fuse and the virus enters into the 
host cell. This results in the development of an infectious disease, called COVID-19, which is associated with 
a major immune inflammatory response. Deaths are caused by respiratory failure, which have been linked to a 
cytokine storm with high serum levels of pro-inflammatory cytokines and  chemokines31. There are currently no 
approved vaccines or drugs that specifically target Coronavirus infection, and, despite several ongoing clinical 
trials, treatment options have been based on different clinical approaches with limited background testing. An 
exponentially growing number of computational studies have tried to provide molecular data in support of these 
novel potential COVID-19  treatments15, 32–34.
The aim of this proof of principle study was to propose a robust in silico protocol that overcame limitations of 
classic virtual screening  studies35. The role of hydration patterns in target recognition and binding is completely 
absent in docking simulations. Furthermore, in most virtual screenings, while the ligand is flexible, proteins are 
only semi-flexible, which affects both the resulting pose of the ligand and the scoring  system36. More reliable 
information can only be obtained by MD simulations, which, despite being computationally expensive, allow to 
take into account macromolecules’ unique features, such as conformational flexibility, charge distribution, and 
hydration patterns in target recognition, drug binding, and drug  unbinding37,38. In this study we coupled dock-
ing with cMD, SuMD and SMD to identify a Spike protein—ACE2 interaction inhibitor. Transmission electron 
microscope image of SARS-CoV-2 have shown how the viral envelope is densely populated by the S protein, 
which, due to its role in pathogenesis, is the main target of neutralizing antibodies and  vaccines39. An analysis 
of the crystal structure of the RBD with ACE2 reveals that the RBD of the S protein has a relatively flat surface, 
which would be unsuitable for drug targeting. Previous studies have shown that the analysis of protein dynam-
ics allows for the identification of transient pockets where small molecules can bind  proteins40. We identified a 
transient pocket with druggability features on the RBD which may represent a hot  spot38. Indeed, comparison 
with the structure of SARS-CoV S protein in complex with a neutralising antibody isolated from a SARS-CoV 
survivor shows that the pocket we identified lies on the same surface recognised by the CDRs of the  antibody39. 
We retrieved the structure of the protein with an open pocket from the trajectory of the MD simulation and we 
used it for a virtual screening of 1582 FDA-approved drugs. The advantage of focusing on FDA-approved drugs 
is that the safety issues are all within suitable bounds and are well understood, meaning that they could proceed 
to clinical trial reasonably quickly. The compounds showing high binding energies and forming a network of 
specific interaction with side chains of residues in the RBD binding pocket were Simeprevir and Lumacaftor. 
Simeprevir, a direct-acting antiviral agent for the treatment of HCV infections, is a second generation of orally 
available NS3/4 HCV protease  inhibitor41. Lumacaftor is a CFTR corrector that stabilises the first transmembrane 
domain of CFTR, resulting in an improved maturation of CFTR  mutants42. The two drugs were also selected for 
their reported minimal off-targeting, suggesting a lack of binding to other human  proteins41,43. Furthermore, 
Kadioglu et al.44 also identified Simeprevir as a potential S protein-ACE2 interaction inhibitor. In a similar 
attempt to overcome limitations of classic in silico docking, they adopted a complex approach combining virtual 
drug screening, molecular docking and supervised machine learning  techniques44. While their results strongly 
reinforce the findings of our study, our strategy provided comprehensive information about the ability of com-
pounds to interfere with the Spike protein binding to ACE2 by combining cMD, SuMD and SMD.
Virtual screening and in vitro studies suggested that Lumacaftor and Simeprevir are also SARS-CoV-2 main 
protease  inhibitors45. Interestingly, several in silico and in vitro studies have identified antiviral agents targeting 
HCV infection (single-stranded negative-sense RNA virus) as promising treatments for COVID-1946, which 
include HCV approved inhibitors of the viral RNA synthesis, the 3CL protease and the helicase  activity46. Anti-
viral agents against HCV infections have also been studied for their promising ability to interfere with other 
viral infections caused by RNA viruses, i.e. SARS-associated  coronavirus47,  MERS48, Enterovirus A71, Herpes 
simplex virus type 1 and Zika  virus41. This would suggest the possibility to use and/or develop Simeprevir into 
broad-spectrum antiviral  drugs41. Simeprevir and Lumacaftor are also promising for their potential ability to 
inhibit multiple steps of the SARS-CoV-2 infection by interfering with the S protein binding to the ACE2 receptor 
and by inhibiting the SARS-CoV-2 main protease, essential for processing the polyproteins that are translated 
from the viral  RNA49. The concept of multi-target drugs that inhibit several proteins simultaneously has been 
successfully used for the treatment of many diseases. For example, the anti-HIV drug Cosalane was developed 
to inhibit binding of the HIV gp120 envelope glycoprotein to CD4 and simultaneously to inhibit the cytopathic 
mechanism of HIV-150.
While writing this paper, several drug repurposing studies targeting the S protein have been published. 
Interestingly, several  papers32,34,44,51 carried out virtual screenings on the same surface we identified as a transient 
pocket. Binding energies of proposed compounds are however lower than the one we observed for Simeprevir 
and Lumacaftor. This is very likely linked to the protein structures used for virtual screening and/or a binding 
pocket not being in the optimal open conformation, highlighting the strength of our in silico approach.
Our results show the importance of taking into account the full structural features of a protein–ligand com-
plex and how a combination of MD simulations may help predict the validity of a proposed inhibitor. Our work 
suggests that Simeprevir and Lumacaftor could be potential initial compounds able to prevent and treat SARS-
CoV-2 infection.
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